---
document_datetime: 2023-09-21 21:56:13
document_pages: 25
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/neurobloc-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: neurobloc-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 15.6879513
conversion_datetime: 2025-12-24 16:00:30.23177
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
EMA/176801/2021

## NeuroBloc

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                      | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0107            | C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority | 04/03/2021                                  | SmPC and                                    | PL                               |           |

Medicinal product no longer authorised

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| PSUSA/428/2 02006   | Periodic Safety Update EU Single assessment - botulinum toxin b                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 11/02/2021   | n/a                           |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------------------------------|
| IA/0105             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 29/05/2020   | n/a authorised                |
| II/0104/G           | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch Medicinal product | 16/01/2020   | 28/04/2020 Annex II no longer |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                   | control/testing takes place B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method                                                                                                   |            |               |                                  | authorised                                                                                                                               |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0103         | B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing                                                                                                                                                                                                                                                                | 28/05/2019 | 28/04/2020    | Annex II and PL                  |                                                                                                                                          |
| IAIN/0102/G       | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing product | 28/05/2019 | 28/04/2020 no | Annex II and PL longer           |                                                                                                                                          |
| T/0101            | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                  | 27/07/2018 | 20/09/2018    | SmPC, Labelling and PL           |                                                                                                                                          |
| PSUSA/428/2 01706 | Periodic Safety Update EU Single assessment - botulinum toxin b Medicinal                                                                                                                                                                                                                                                                                                                            | 22/02/2018 | 23/04/2018    | SmPC, Annex II, Labelling and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/428/201706. |
| N/0100            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                     | 10/11/2017 | 23/04/2018    | PL                               |                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| IB/0098/G         | This was an application for a group of variations. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                    | 07/04/2017   | 23/04/2018   | SmPC                                         |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------------------|
| PSUSA/428/2 01406 | Periodic Safety Update EU Single assessment - botulinum toxin b                                                                                                                                                                                                                                                                                                                                                         | 12/02/2015   | n/a          | PRAC Recommendation - maintenance authorised |
| IAIN/0096         | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                          | 06/06/2014   | n/a no       | longer                                       |
| IAIN/0095         | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP product                                                                                                                                                                  | 05/03/2014   | n/a          |                                              |
| IB/0094           | Update of Product Information in line with the most recent version of the QRD template (Version 9, 03/2013). Linguistic corrections required to align the Product Information with the national language templates have also been included in the updates besides a few additional minor changes. The MAH has also taken this opportunity to update the representative information in the Patient Information Medicinal | 26/02/2014   | 19/02/2015   | SmPC, Annex II and PL                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | Iceland as well as introducing details for Croatia in accordance with QRD template Version 9. Removal of the wording concerning 'An updated RMP shall be submitted annually until renewal' in Annex Section D, as a renewal was granted in 2010 with unlimited validity. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation   | Leaflet for Belgium, Luxembourg, Hungary and II,   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|
| II/0092   | To add an alternative source of an excipient used in the manufacturing of Neurobloc. B.II.a.3.b.3 - Changes in the composition (excipients) of the finished product - Other excipients - Change that relates to a biological/immunological product no                                                                                                                     | 23/01/2014                                         |
| IA/0093   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient product                                                                                                                      | 20/12/2013                                         |
| IB/0090   | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                | 26/09/2013                                         |
| IA/0089/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder Medicinal                                                                                                                                                                                                          | 19/09/2013                                         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient   |            |               |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|
| IAIN/0091 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                          | 18/09/2013 | n/a           |
| IG/0345   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                         | 03/09/2013 | n/a no longer |
| IAIN/0087 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP product                                                                                                                                  | 31/07/2013 | n/a           |
| N/0086    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) Medicinal                                                                                                                                                                                                                                                                              | 02/07/2013 | 21/02/2014    |
| IAIN/0084 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                          | 06/05/2013 | n/a           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IAIN/0083/G   | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                       | 31/01/2013   | n/a           |
|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|
| IB/0082/G     | This was an application for a group of variations. B.V.a.1.b - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - First-time inclusion of a new PMF NOT affecting the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier Medicinal product | 17/01/2013   | n/a no longer |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP product   | no         | longer authorised                |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------|
| II/0078 | C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH 17/01/2013 Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 21/02/2014 | SmPC, Annex II, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| IB/0080   | B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                 | 14/12/2012   | n/a                                           |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----------------------------------------------|
| IB/0079/G | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 06/11/2012   | n/a                                           |
| IB/0076/G | This was an application for a group of variations. B.I.a.4.f - Change to in-process tests or limits applied during the manufacture of the AS - Addition or replacement of an in-process test as a result of a safety or quality issue B.I.a.4.f - Change to in-process tests or limits applied during the manufacture of the AS - Addition or replacement of an in-process test as a result of a    | 06/06/2012   | safety or quality issue n/a product no longer |
| II/0075   | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range Medicinal                                                                                                                                                                                                                                       | 24/05/2012   | n/a                                           |
| IA/0077   | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting                                                                                                                                                                                                                                                                                                                 | 16/05/2012   | n/a                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |                      |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------|
| II/0071/G | This was an application for a group of variations. Replacement of a manufacturing site for the finished product. Change in immediate packaging of the finished product. Change in source of an excipient with TSE risk. Change in the supplier of packaging components. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/immunological medicinal products. B.II.e.1.z - Change in immediate packaging of the finished product - Other variation B.II.c.3.z - Change in source of an excipient or reagent with TSE risk, other change B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the product | 22/09/2011 | 22/09/2011 no longer |
| IB/0073   | dossier) - Replacement or addition of a supplier B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 22/07/2011 | n/a                  |
| IB/0072   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 22/07/2011 | n/a                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                    |                    |                                                       | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0070 | Type IB Variation to update Annex IIB to include the key messages of the additional risk minimisation activities described in the Risk Minimisation Plan. C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with | 31/01/2011         | n/a Annex II                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| R/0067  | NO new additional data are submitted by the MAH Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                              | 23/09/2010 product | 29/11/2010 SmPC, Annex II, Labelling and PL no longer | Based on the review of the available information the CHMP is of the opinion that the quality, safety and efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and considers that the benefit/risk profile of Neurobloc continues to be favourable. The CHMP therefore recommended that a renewal can be granted with unlimited validity. Within the renewal procedure the MAH provided the results of an analysis of hypersensitivity type reactions. Based on these results the CHMP recommended the inclusion of the terms angioedema, rash, urticaria and pruritus in the paragraph on post-marketing experience in section 4.8 of the SPC. The Product Information was further updated to be in |
| IB/0069 | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS Medicinal                                                                                                                                                                                                                                           | 08/09/2010         | n/a                                                   | line with the current QRD requirements and SmPC guideline.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| IA/0068   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes                                                                                                                                                                 | 20/07/2010   | n/a           | do not affect the properties of the FP   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|------------------------------------------|
| IA/0066   | To amend the marketing authorisation dossier for Neurobloc with an approved 2nd step PMF re-certification procedure regarding human Serum Albumin excipient. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes FP | 30/03/2010   | n/a longer    | do not affect the properties of the      |
| II/0064   | Replacement of reference standards for the active substance and for the finished product. Update of or change(s) to the pharmaceutical documentation product                                                                                                                                                                                                            | 21/01/2010   | 02/02/2010 no |                                          |
| II/0063   | Changes in test procedure for active substance and finished product. Update of or change(s) to the pharmaceutical documentation Medicinal                                                                                                                                                                                                                               | 21/01/2010   | 02/02/2010    |                                          |
| N/0065    | Update of local representatives in Bulgaria, Czech Republic, Cyprus, Finland, France, Greece, Hungary, Latvia, Malta and Slovak Republic together with minor                                                                                                                                                                                                            | 11/01/2010   | n/a           |                                          |

<div style=\"page-break-after: always\"></div>

|         | grammatical/typographical corrections in the Danish labelling. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0062 | Change in one of the chromatographic steps in the purification of the drug substance. Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 24/09/2009 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0061 | Update of Summary of Product Characteristics (SPC) and Package Leaflet (PL). To update sections 4.2, 4.4 and 5.1 of the SPC to reflect immunological data from two clinical studies in patients with cervical dystonia. Section 3 of the PL has been updated accordingly. This variation also fulfils FUM2 019.4 and FUM2 003.2. The MAH took the opportunity to correct the list of local representatives from Austria and Portugal in section 6 of the PL. In addition, the MAH made editing correction to section 4 of the PL. Update of Summary of Product Characteristics and Package Leaflet Medicinal product | 25/06/2009 | The SPC of NeuroBloc has been updated with immunological information from two completed Phase IV post-marketing studies that evaluate the safety and immunogenicity of NeuroBloc (Botulinum Toxin Type B) in patients with cervical dystonia. In the first study (AN 072-401 CD-EU), 130 patients were enrolled, including 67 patients resistant and 63 responders to Botulinum Toxin Type A respectively. The objective of this study was to evaluate the safety and evaluate immunogenicity of repeat doses of NeuroBloc in subjects with cervical dystonia (CD) by assessing clinical safety parameters, laboratory tests, and adverse events (AEs). The second study (AN072-402CD-EU) compared effectiveness, safety and duration of action of Botulinum Toxin Types A and B in subjects who had never previously received a botulinum toxin. Both studies suggest that the presence of antibodies was not synonymous with a loss of clinical response with impact on the overall safety profile. The Product Information was therefore updated to reflect the |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                          |                    |                                   | mentioned findings.                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2PMF/0059 | Inclusion of the updated or amended Plasma Master File (Grifols EMEA/H/PMF/000002/04) in the marketing authorisation dossier                                                                                                                                                                                             | 02/04/2009         | n/a                               | authorised                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0053   | The Marketing Authorisation Holder applied to add an additional storage period of 3 months when stored below 25 C, to facilitate holding of the product prior to use.                                                                                                                                                    | 19/02/2009         | 25/03/2009                        | SmPC, Labelling and PL                                                                                                                                                                                                                                                                                                                                                                                                           |
| IB/0058   | Change(s) to shelf-life or storage conditions IB_38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient                                                                                                                                                                         | 12/03/2009         | n/a longer                        |                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0060   | IA_01_Change in the name and/or address of the marketing authorisation holder                                                                                                                                                                                                                                            | 12/03/2009         | n/a SmPC, Labelling and no        |                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0057   | IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing                                                                                                                                                                                                                         | 13/02/2009 product | PL n/a Annex II and               | PL                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IB/0056   | IB_20_c_Change in test procedure for an excipient - other changes                                                                                                                                                                                                                                                        | 02/02/2009         | n/a                               |                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0055   | Update of section 4.8 of the Summary SPC to include the adverse event 'dyspnoea' based on data from PSUR 8 (covering the period from 20.07.05 to 30.06.08). Section 4 of the PL was updated accordingly. In addition, section 4 of the PL was updated with the adverse event 'headache', in line with the SPC. Medicinal | 18/12/2008         | 30/01/2009 SmPC, Labelling and PL | A cumulative review of the MAH's safety database up to 30 June 2008 identified 25 reports of dyspnoea. Seventeen (17) of these reports were related to off-label use (3 reports involving children or adolescents, 16 reports involving non approved indications, 8 involving patients with underlying neurological disease). Four (4) of the patients with dyspnoea had symptoms suggestive of allergic reaction. Not all cases |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | The MAH also took the opportunity to remove the warning on albumin from section 4.4 of the SPC and section 3 of the PL, as recommended by the CHMP in April 2008. The MAH also made minor corrections to the labelling for Bulgaria, Czech Republic, Estonia, Denmark, Finland, Germany, Hungary, Iceland, Lithuania, Latvia, Poland, Norway, Slovakia, Slovenia and Sweden. Update of Summary of Product Characteristics, Labelling and Package Leaflet   |                          | longer          | of dyspnoea appeared to be related to NeuroBloc administration and other morbidities may be more likely etiologies; however it is not possible to exclude a role of NeuroBloc in these events. Some patients also experienced other events of possible toxin spread. Based on this review, 'dyspnoea' has been added to the SPC among the side effects related to spread of toxin distant from the site of administration. authorised   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0054 | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                                                                                                                                                                            | 18/12/2008 05/01/2009    |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0049 | The Marketing Authorisation Holder applied to introduce a new reference standard used for analyses of the concentrated product. Change(s) to the manufacturing process for the finished product product                                                                                                                                                                                                                                                    | 25/09/2008 01/10/2008 no |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| N/0050  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                           | 26/09/2008 n/a           | PL              |                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IA/0051 | IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing Medicinal                                                                                                                                                                                                                                                                                                                                                 | 05/09/2008 n/a           | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IA/0052 | IA_25_b_02_Change to comply with Ph. - compliance with EU Ph. update - excipient                                                                                                                                                                                                                                                                                                                                                                           | 04/09/2008 n/a           |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| II/0047   | Change(s) to the manufacturing process for the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                    | 24/07/2008         | 31/07/2008    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MF/0048   | 2PMF (2nd step of PMF certification procedure)                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 16/06/2008         | n/a           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0044   | Update of Summary of Product Characteristics and Labelling. Update of section 5.1 of the SPC to reflect final data from an open label safety and immunogenicity study of NeuroBloc in patients with cervical dystonia. The MAH also took the opportunity to make a minor correction in section 4.8. In addition, section 9 of the SPC and section 16 of the Labelling have been updated in line with the EMEA QRD template version 7.2. Update of Summary of Product Characteristics and Labelling | 24/01/2008         | 26/02/2008 no | SmPC and Labelling A post-marketing open label clinical study was performed by the MAH as a post-authorisation commitment to evaluate the safety and immunogenicity of NeuroBloc (Botulinum Toxin Type B) in patients with cervical dystonia previously treated with Botulinum Toxin Type A. Interim results of this study were already reflected in the SPC. The study has now been completed and its description has been updated in the SPC. A total of 130 patients were enrolled, including 67 patients resistant to Botulinum Toxin Type A and 63 patients responsive to Botulinum Toxin Type A. The final results showed that the safety profile of NeuroBloc was similar in both types of patients and no new safety concerns were identified. The immunogenicity results will be submitted at a longer authorised |
| IA/0046   | IA_16_b_Submission of new TSE certificate relating to active substance - other substances                                                                                                                                                                                                                                                                                                                                                                                                          | 05/02/2008         | n/a           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IA/0045   | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                                                                                                                                                                                                                                                  | 10/01/2008 product | n/a           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| T/0043    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 23/08/2007         | 25/09/2007    | SmPC, Labelling and Transfer of the Marketing Authorisation from Solstice Neurosciences Ltd. to Eisai Limited.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0041   | Update of Summary of Product Characteristics, Annex II, Labelling and Package Leaflet Medicinal                                                                                                                                                                                                                                                                                                                                                                                                    | 19/07/2007         | 21/08/2007    | SmPC, Annex Labelling Final results of a post-marketing clinical study comparing the safety and efficacy of botulinum toxin type B (NeuroBloc) with botulinum toxin type A (Botox) in patients with cervical                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|         | Update of sections 4.8 and 5.1 of the SPC to reflect the final results from a Phase IV clinical study designed to compare the safety and efficacy of NeuroBloc (botulinum toxin type B) with botulinum toxin type A in patients with cervical dystonia who have never received previously a botulinum toxin product. Section 4 of the PL was updated accordingly. The MAH also took the opportunity to update the product information according to the latest EMEA/QRD template (version 7.2). Update of Summary of Product Characteristics, Labelling and Package Leaflet   |                       | and PL      | dystonia (torticollis) never previously treated with botulinum toxin products showed that NeuroBloc is not inferior to Botox in terms of efficacy. In terms of safety, the most common undesirable effects in patients treated with NeuroBloc were dry mouth and dysphagia, which were reported at a frequency of 44% and 35% respectively, which was significantly higher than the rates observed with botulinum toxin type A. authorised                                                                                                                                                                                                                                                                                                                                          |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0042 | Change(s) to the test method(s) and/or specifications for the active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 19/07/2007 10/08/2007 | longer      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| MF/0040 | 2PMF (2nd step of PMF certification procedure)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 26/04/2007 n/a no     |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0039 | Update of sections 4.4 and 4.8 of the SPC to include information on adverse spread reactions as requested by the CHMP in November 2006. Sections 2 and 4 of the PL were updated accordingly. Update of Summary of Product Characteristics and Package Leaflet Medicinal product                                                                                                                                                                                                                                                                                              | 22/02/2007 28/03/2007 | SmPC and PL | Distant reactions including muscle weakness, dysphagia and aspiration represent a significant proportion of all reported serious events associated with the use of botulinum toxin containing products. These adverse effects are temporary and usually disappear within a few weeks. However, fatal cases have been reported and the botulinum toxin is likely to have contributed to some of those cases. The majority of the fatal cases reported also had underlying medical conditions such as neurological disorders and prior histories of dysphagia or aspiration. Although dysphagia and aspiration pneumonia were already mentioned in the SPC, the CHMP considered that the issue of distant spread of the toxin as well as the need for caution in vulnerable patients, |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                      |                    |                                             | particularly those with underlying neurological disorders should also be adequately addressed in the product information.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------|------------------------------------------------------------------------------------------------------|--------------------|---------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0036 | Change(s) to the manufacturing process for the active substance                                      | 16/11/2006         | 27/11/2006                                  | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA/0038 | IA_05_Change in the name and/or address of a manufacturer of the finished product                    | 30/10/2006         | n/a Annex II and PL                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0037 | IA_12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening of spec. | 21/07/2006         | n/a                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0035 | Change(s) to the test method(s) and/or specifications for the finished product                       | 28/06/2006         | 06/07/2006 no longer                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| R/0033  | Renewal of the marketing authorisation. Medicinal                                                    | 14/12/2005 product | 06/04/2006 SmPC, Annex II, Labelling and PL | There are no major differences on the efficacy and safety evaluations of Neurobloc after 5 years on the Market. Although it is worth noting that a number of studies were conducted and their data made the benefit risk assessment more robust. It should be mentioned that there is an overall concern on the class of botulinum toxins regarding dysphagia and fatal outcomes. This is not specific of Neurobloc but of the whole class. Final reports of the studies that will be concluded in 2006 should be delivered when ready as per commitment timetables. Based on the re-evaluation of the benefit/risk balance, the |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                   |                    |               |             | Marketing Authorisation of the medicinal product can be considered for renewal. However, due to the above-mentioned safety concern and waiting for final reports of studies being conducted, the CHMP recommended the MAH should submit one additional renewal in 5 years time.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0034 | Update of section 4.4 of the SPC to include a warning about aspiration pneumonia and/or potentially fatal respiratory disease in patients with respiratory distress or difficulty in swallowing following the assessment of a clinical follow-up measure (from PSUR 5 covering the period 01/01/03 - 31/12/03) and the assessment of PSUR 6 covering the period 01/01/04 - 31/12/04. Update of Summary of Product Characteristics | 13/10/2005 product | 15/11/2005 no | SmPC longer | Following the assessment of PSUR 5 the CHMP requested clarification on the analyses of all fatal cases associated with the use of NeuroBloc. The data submitted showed that the 3 cases presented only reinforced the need to closely monitor the cases of death and stroke and the need to evaluate the inclusion of aspiration pneumonia in the safety information of Neurobloc. In PSUR 6 a cumulative analysis of all fatal cases associated with the use of Botulinum Toxin type B was presented. During the covered period 17 fatal cases from a total of 693 cases were reported. Of those, 7 originated from post marketing sources, 5 cases from clinical trials, and 5 from the Medical Index for Neuromuscular Data (MIND) registry. Aspiration pneumonia and death related to respiratory distress/aspiration pneumonia accounted for 6 in 17, that is to say, 35% of all fatal cases. This variation addresses the request of the CHMP to include a warning about aspiration pneumonia in patients with respiratory distress or difficulty in swallowing. authorised |
| II/0031 | Change(s) to shelf-life or storage conditions                                                                                                                                                                                                                                                                                                                                                                                     | 15/09/2005         | 19/10/2005    | SmPC        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0032 | Change(s) to the test method(s) and/or specifications for the finished product Medicinal                                                                                                                                                                                                                                                                                                                                          | 15/09/2005         | 22/09/2005    |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| T/0030   | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                       | 04/08/2005         | 26/08/2005    | SmPC, Labelling and PL   | The Marketing Authorisation for Neurobloc was transfered from Elan Pharma International Ltd to Solstice Neurosciences                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0029  | Update of section 5.1 \"Pharmacodynamic Properties\" of the Summary of Product Characteristics to reflect the results of an interim report of the Study AN072-401 on immunogenicity of NeuroBloc in Botulinum Toxin Type A resistant patients. Update of Summary of Product Characteristics | 23/06/2005         | 16/08/2005 no | SmPC longer              | Ltd. An interim analysis of the development of neutralising antibodies to NeuroBloc was performed in 67 Botulinum Toxin Type A-resistant subjects after at least 50 subjects had completed four cycles of NeuroBloc (Botulinum Toxin Type B) treatment. On the first year of treatment the number of patients that developed antibodies to Botulinum Toxin Type B was low, about 5%. It should be born in mind that presence of antibodies does not necessarily equal resistance to treatment, i.e. the number of truly resistant patients could be lower than the number of patients who develop antibodies. On the second year, the rate of patients with antibodies increased. However, the overall number of patients treated was small. So far, these data suggest that, at least during one year, resistant patients to Botulinum Toxin Type A may benefit from Botulinum Toxin Type B, which is of importance. These results have been incorporated into the SPC Section 5.1. \"Pharmacodynamic Properties\". authorised |
| S/0025   | Fourth annual reassessment. Medicinal                                                                                                                                                                                                                                                     | 21/04/2005 product | 08/07/2005    | Annex II                 | On the basis of the data submitted, the benefit/risk in the treatment of cervical dystonia (torticollis) in patients responsive and resistant to Botulinum toxin type A preparations remains positive. No amendments of Annexes I and III of the Marketing Authorisation were necessary. However, it was necessary to update the Annex II.C of the CHMP Opinion as the remaining                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                    |                                           | Specific Obligation (to conduct a Phase IV clinical study to demonstrate the non-inferiority of NeuroBloc (Botulinum Toxin Type B) to Botulinum Toxin Type A (Botox) in patients with cervical dystonia who have never previously received a Botulinum toxin product) could be considered finalised. The primary results of this study were previously reflected in the Type II variation II/0024. The MAH has commited to provide the final report by 2Q2006. The CHMP finally agreed that there are no grounds for the Marketing Authorisation to remain under exceptional circumstances. authorised                                                                                                                |
|---------|--------------------------------------------------------------------------------------------------------------------|-------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0027 | Change(s) to the test method(s) and/or specifications for the active substance                                     | 23/06/2005 27/06/2005 longer              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0028 | Change(s) to the manufacturing process for the active substance                                                    | 26/05/2005 02/06/2005 no                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0023 | Further to post-marketing surveillance. Update of Summary of Product Characteristics and Package Leaflet Medicinal | 17/02/2005 29/03/2005 SmPC and PL product | The SPC was updated in its sections: - 4.8 \"Undesirable effects\" to reflect that 70% of the dysphagia cases reported were serious and required medical intervention. This update was requested following PSUR 5 (01.01.2003 - 31.12.2003) where four cases were identified where dysphagia occurred with unexpected severity. - 5.2 \"Pharmacokinetic Properties\" to reflect that on a total of 552 cases reported from January 2001 to December 2003, 165 (30%) were serious cases, of which 66 were serious cases with possible systemic effects, meaning 12% of the total cases. These reports during the post-marketing experience included the following adverse events: dry mouth, dysphagia and blurred vision. |

<div style=\"page-break-after: always\"></div>

| II/0024   | Further to results of a phase IV clinical study. Update of Summary of Product Characteristics      | 20/01/2005         | 28/02/2005 no   | SmPC longer           | The SPC was updated in its section 5.1 \"Pharmacodynamic Properties\" to reflect the results of a Phase IV study conducted to demonstrate the non-inferiority of NeuroBloc to botulinum toxin type A in patients with cervical dystonia who have never previously received a botulinum toxin product. An interim analysis was carried out on the total of 111 enrolled botulinum naive enrolled patients (56 in the NeuroBloc group) following a single injection, into 2 of 4 predetermined muscles, of NeuroBloc 10,000 units or botulinum toxin type A 150 units. The analysis showed that there were no clinically relevant differences between these two treatments. The primary analysis of non-inferiority with the per-protocol population was not proven (90% CI of difference -2.66, 4.01 compared with an upper limit of <4.00), however, a sensitivity analysis for robustness and a confirmatory ITT population analysis (90% CI of difference -3.4, 3.2 and -3.23, 2.98 respectively) authorised   |
|-----------|----------------------------------------------------------------------------------------------------|--------------------|-----------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0026   | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.) | 09/02/2005         | n/a             | Annex II              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| S/0019    | Third Annual Reassessment. Medicinal                                                               | 22/04/2004 product | 17/12/2004      | SmPC, Annex II and PL | demonstrated non-inferiority. On the basis of the data submitted since the Marketing Authorisation, the benefit/risk in the symptomatic treatment of cervical dystonia in patients responsive and resistant to Botulinum toxin type A preparations remains positive. There was however the necessity to update the Annexes of the opinion as follows: a. the Annex I, according to the latest EMEA/QRD template, b. the Annex II, according to the latest EMEA/QRD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |                             | template and to revise Annex II.C to the Commission Decision, in order to update the remaining Specific Obligation, c. the Annex III, to revise the list of local representatives in the Package Leaflet. The CPMP agreed that the Marketing Authorisation should remain under exceptional circumstances. authorised   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0022 | Quality changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 16/09/2004 | 21/09/2004                  | Quality change to site of product manufacture.                                                                                                                                                                                                                                                                         |
| II/0021 | Quality changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 16/09/2004 | 21/09/2004                  | Quality changes to amend the analytical test methods.                                                                                                                                                                                                                                                                  |
| IA/0020 | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                                                                                                                                                                                                                                               | 24/03/2004 | n/a Annex II and and longer | PL                                                                                                                                                                                                                                                                                                                     |
| II/0016 | The MAH applied for changes to the sections 4.8 \"Undesirable effects\" and 5.2 \"Pharmacokinetics properties\" of the SPC further to the evaluation of PSUR4 covering the period from 1 July 2002 to 31 December 2002. In addition, an amendment to section 5.3 \"Preclinical Safety Data\" is proposed to remove an inconsistency remaining from the previous variation. The Package Leaflet has been updated accordingly. Update of Summary of Product Characteristics and Package Leaflet product | 20/11/2003 | 29/01/2004 SmPC no          | PL                                                                                                                                                                                                                                                                                                                     |
| IB/0017 | IB_19_b_Change in specification of an excipient - addition of new test parameter Medicinal                                                                                                                                                                                                                                                                                                                                                                                                      | 11/12/2003 | n/a                         |                                                                                                                                                                                                                                                                                                                        |
| I/0018  | IB_19_b_Change in specification of an excipient - addition of new test parameter                                                                                                                                                                                                                                                                                                                                                                                                                | 11/12/2003 | n/a                         |                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| II/0014   | sections 4.6 and 5.3 Update of Summary of Product Characteristics                              | 22/05/2003   | SmPC                          |
|-----------|------------------------------------------------------------------------------------------------|--------------|-------------------------------|
| I/0015    | 24_Change in test procedure of active substance                                                | 29/08/2003   | 05/09/2003 authorised         |
| S/0013    | Annual re-assessment.                                                                          | 25/04/2003   | 15/07/2003 Annex II           |
| II/0009   | Update of Summary of Product Characteristics and Package Leaflet                               | 18/12/2002   | 07/03/2003 SmPC and PL longer |
| I/0012    | 12_Minor change of manufacturing process of the active substance                               | 18/12/2002   | 19/12/2002 no                 |
| II/0010   | Change(s) to the test method(s) and/or specifications for the finished product                 | 21/11/2002   | 26/11/2002 product            |
| I/0011    | 01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process | 08/11/2002   | n/a                           |
| S/0008    | Annual re-assessment.                                                                          | 25/04/2002   | 25/04/2002                    |
| I/0007    | 15_Minor changes in manufacture of the medicinal product Medicinal                             | 08/03/2002   | 18/03/2002                    |
| I/0006    | 16_Change in the batch size of finished product                                                | 15/02/2002   | 28/02/2002                    |
| N/0005    | Minor change in labelling or package leaflet not                                               | 12/09/2001   | PL                            |

<div style=\"page-break-after: always\"></div>

|        | connected with the SPC (Art. 61.3 Notification)                                                  |                       |
|--------|--------------------------------------------------------------------------------------------------|-----------------------|
| I/0001 | 20_Extension of shelf-life as foreseen at time of authorisation                                  | 18/05/2001 04/07/2001 |
| I/0002 | 17_Change in specification of the medicinal product                                              | 31/05/2001 21/06/2001 |
| N/0003 | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 23/05/2001 02/07/2001 |
| I/0004 | 12_Minor change of manufacturing process of the active substance                                 | 18/05/2001 n/a        |

Medicinal product no longer authorised